Formula Tolerance of Term Infants

NCT ID: NCT04915937

Last Updated: 2022-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-13

Study Completion Date

2022-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the effects of infant formula with oligosaccharides on symptoms of formula intolerance in healthy, term infants

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastro-Intestinal Tolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Infant Formula

Feed ad libitum during study period

Group Type EXPERIMENTAL

Study Infant Formula

Intervention Type OTHER

RTF milk-based infant formula with oligosaccharides

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Study Infant Formula

RTF milk-based infant formula with oligosaccharides

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is judged to be in good health as determined from participant's medical history by parent report
* Participant is a singleton from a full-term birth with a gestational age of 37-42 weeks.
* Participant's birth weight was \>= 2490 g (\~5 lbs. 8 oz.)
* Participant was identified by parents as very fussy or extremely fussy in the Baseline Tolerance Evaluation on a formula-feed
* Participant is exclusively formula-fed at time of study entry and Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study, unless instructed otherwise by their healthcare professional.
* Parent(s) confirm their intention not to administer vitamin, mineral, human milk oligosaccharide(s) (HMO), prebiotic(s), or probiotic(s) supplements (with the exception of vitamin D supplements if instructed by their healthcare professional), non-study formula, foods, juices, or other sources of nutrition to their infant from enrollment through the duration of the study
* Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) and provided applicable local privacy regulation authorization prior to any participation in the study

Exclusion Criteria

* An adverse maternal, fetal, or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development. This includes but is not limited to suspected maternal substance abuse.
* Participant is taking and plans to continue taking medications (including OTC, such as Mylicon® for gas), home remedies (such as juice for constipation), herbal preparations, or rehydration fluids that might affect GI tolerance.
* Participant participates in another study that has not been approved as a concomitant study
* Participant has been fed a formula with greater than 2 HMOs prior to study enrollment
* Participant has been fed an extensively hydrolyzed, amino acid based, or preterm formula within 14 days prior to study enrollment and/or an extensively hydrolyzed, amino acid based, or preterm formula has been recommended by the physician.
* Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent
* Participant has been treated with antibiotics within 7 days prior to enrollment
Minimum Eligible Age

7 Days

Maximum Eligible Age

65 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Nutrition

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elizabeth Reverri, PhD, MS, RD

Role: STUDY_CHAIR

Abbott Nutrition

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MedPharmics, LLC

Phoenix, Arizona, United States

Site Status

Dade Research Center, LLC

Miami, Florida, United States

Site Status

Meridian Clincial Research- Macan

Macon, Georgia, United States

Site Status

Clinical Research Prime

Idaho Falls, Idaho, United States

Site Status

Springs Medical Research

Owensboro, Kentucky, United States

Site Status

MedPharmics

Covington, Louisiana, United States

Site Status

Boeson Research Kalispell

Kalispell, Montana, United States

Site Status

Meridian Clinical Research

Hastings, Nebraska, United States

Site Status

Be Well Clinical Studies

Lincoln, Nebraska, United States

Site Status

AVIATI Healthcare & Clinical Research

Memphis, Tennessee, United States

Site Status

Invesclinic US LLC

Edinburg, Texas, United States

Site Status

Maximos Ob/Gyn

League City, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AL41

Identifier Type: -

Identifier Source: org_study_id